Shahar A, Hod H, Barabash G M, Kaplinsky E, Motro M
Emergency Department and Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel.
Cardiology. 1994;85(3-4):255-8. doi: 10.1159/000176683.
The incidence of the post-myocardial infarction syndrome (Dressler's syndrome) among thrombolized patients has not been established yet. To clarify this issue we prospectively studied 201 consecutive patients with acute myocardial infarction who had undergone recombinant tissue-type plasminogen activator therapy followed by 5 days of heparin administration. All patients were followed for at least 3 months for clinical signs of Dressler's syndrome. None of the 148 patients (76%) who showed clinical signs of early reperfusion had Dressler's syndrome. The sole patient in the group who manifested the syndrome developed it 3 weeks following extensive anterior myocardial infarction with no evidence of reperfusion. Although 4 patients manifested signs of early pericarditis, none developed the syndrome. We conclude that Dressler's syndrome has in fact been rendered a rare phenomenon among patients who benefit from thrombolytic therapy.
溶栓治疗患者中心肌梗死后综合征(德雷斯勒综合征)的发病率尚未确定。为了阐明这一问题,我们前瞻性地研究了201例连续的急性心肌梗死患者,这些患者接受了重组组织型纤溶酶原激活剂治疗,随后给予5天肝素治疗。所有患者均随访至少3个月,以观察德雷斯勒综合征的临床症状。148例(76%)出现早期再灌注临床症状的患者均未患德雷斯勒综合征。该组中唯一出现该综合征的患者是在广泛前壁心肌梗死后3周出现的,且无再灌注证据。尽管有4例患者出现早期心包炎症状,但均未发展为该综合征。我们得出结论,在受益于溶栓治疗的患者中,德雷斯勒综合征实际上已成为一种罕见现象。